Mary Beckerle, a whitewater kayaker, has advice for all the folks in the cancer field: never catastrophize, never panic.
While doing somewhat-routine reporting on this year’s Senate Appropriations Committee bills, Paul Goldberg, editor and publisher of The Cancer Letter, quickly realized that he was seeing a full bipartisan rejection of President Donald J. Trump’s plan to defund and therefore dismantle biomedical research in the United States.
Do multi-cancer detection tests provide a net benefit? NCI aims to answer this question, beginning with the Vanguard feasibility trial which recently started accruing patients.
NIH has announced it will stop issuing funding opportunities solely dedicated to animal models, but has not published any formal guidance related to the announcement, and researchers are unclear on when or whether further policy materials are to be expected.
“I don’t think any good cancer center director would be worth their weight in salt if they weren’t worried about something at night,” said Mark Evers, director of University of Kentucky Markey Cancer Center.
A new model aims to change the standard of care around medical debt by addressing the financial toll of cancer using a multidisciplinary, tumor board model approach. Now, recent five-year data shows that it’s working.
In last week’s issue of The Cancer Letter, the cover story featured Col. Susan Fondy, an Army veteran and stage 3 breast cancer survivor, who is now living with lymphedema. Fondy is now a lymphedema advocate, working to prevent further cuts to the already-sparse funding for the disease.
MD Anderson and Texas Children’s Hospital have entered into a collaboration to build a $1 billion pediatric cancer hospital. The hospital, tentatively slated to open in 2031 or 2032, is on track to become one of the largest pediatric cancer hospitals in the world.
A 25-year old idea, a concept named “the American Centers for Cures,” proposed by Lou Weisbach, a former CEO of a Fortune 500 company and a political insider, aims to shift the paradigm of research funding.
In this episode of The Cancer Letter Podcast, Jacquelyn and Paul talk about the first meeting of the National Cancer Advisory Board, the uncertainty of cancer registries, and about choosing what to cover as the Trump administration “floods the zone.”
